Can Fite Biopharma Ltd (CANF) — Net Asset Quality Index
Can Fite Biopharma Ltd (CANF) has a Net Asset Quality Index of 58.8% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of ILA9.51 Million minus total liabilities of ILA3.92 Million yields net assets of ILA5.59 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check Can Fite Biopharma Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Can Fite Biopharma Ltd Net Asset Quality Index Over Time (2003–2025)
This chart shows how Can Fite Biopharma Ltd's Net Asset Quality Index has evolved across 23 annual periods from 2003 to 2025. As of December 2025, the index stands at 58.8%, representing net assets of ILA5.59 Million against total assets of ILA9.51 Million ILA. See working capital position of Can Fite Biopharma Ltd to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Can Fite Biopharma Ltd (2003–2025)
The table below presents the year-by-year Net Asset Quality Index for Can Fite Biopharma Ltd from 2003 to 2025, covering 23 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see CANF market cap.
| Year | Quality Index | Net Assets (ILA) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 58.8% | ILA5.59 Million | ILA9.52 Million | ILA3.92 Million | ▼ -0.8 pp |
| 2024 | 59.6% | ILA5.44 Million | ILA9.12 Million | ILA3.68 Million | ▼ -2.9 pp |
| 2023 | 62.5% | ILA6.24 Million | ILA9.99 Million | ILA3.75 Million | ▲ +14.3 pp |
| 2022 | 48.2% | ILA4.47 Million | ILA9.28 Million | ILA4.81 Million | ▼ -22.8 pp |
| 2021 | 71.0% | ILA14.38 Million | ILA20.25 Million | ILA5.87 Million | ▲ +7.2 pp |
| 2020 | 63.8% | ILA6.07 Million | ILA9.52 Million | ILA3.45 Million | ▲ +33.9 pp |
| 2019 | 29.9% | ILA2.44 Million | ILA8.17 Million | ILA5.73 Million | ▼ -8.0 pp |
| 2018 | 37.9% | ILA3.02 Million | ILA7.95 Million | ILA4.94 Million | ▼ -1.1 pp |
| 2017 | 39.0% | ILA3.05 Million | ILA7.83 Million | ILA4.78 Million | ▲ +0.9 pp |
| 2016 | 38.1% | ILA3.87 Million | ILA10.17 Million | ILA6.29 Million | ▼ -21.2 pp |
| 2015 | 59.3% | ILA10.44 Million | ILA17.60 Million | ILA7.16 Million | ▼ -8.0 pp |
| 2014 | 67.3% | ILA6.86 Million | ILA10.19 Million | ILA3.33 Million | ▲ +0.1 pp |
| 2013 | 67.2% | ILA4.46 Million | ILA6.63 Million | ILA2.18 Million | ▲ +110.5 pp |
| 2012 | -43.3% | ILA-707.99K | ILA1.64 Million | ILA2.34 Million | ▼ -110.4 pp |
| 2011 | 67.1% | ILA3.29 Million | ILA4.90 Million | ILA1.61 Million | ▼ -3.4 pp |
| 2010 | 70.5% | ILA13.07 Million | ILA18.55 Million | ILA5.47 Million | ▲ +3.4 pp |
| 2009 | 67.1% | ILA13.49 Million | ILA20.10 Million | ILA6.62 Million | ▼ -0.6 pp |
| 2008 | 67.7% | ILA14.79 Million | ILA21.86 Million | ILA7.07 Million | ▼ -11.4 pp |
| 2007 | 79.1% | ILA38.70 Million | ILA48.94 Million | ILA10.23 Million | ▼ -12.7 pp |
| 2006 | 91.8% | ILA38.34 Million | ILA41.76 Million | ILA3.42 Million | ▼ -4.8 pp |
| 2005 | 96.6% | ILA35.83 Million | ILA37.09 Million | ILA1.26 Million | ▲ +237.8 pp |
| 2004 | -141.2% | ILA-1.81 Million | ILA1.28 Million | ILA3.09 Million | ▼ -217.5 pp |
| 2003 | 76.3% | ILA2.07 Million | ILA2.71 Million | ILA642.00K | — |